KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetShares Issued
Ratios

Abbott Laboratories (ABT) Accumulated Depreciation & Amortization (2016 - 2025)

Abbott Laboratories (ABT) has disclosed Accumulated Depreciation & Amortization for 17 consecutive years, with $13.4 billion as the latest value for Q4 2025.

  • Quarterly Accumulated Depreciation & Amortization rose 10.96% to $13.4 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $13.4 billion through Dec 2025, up 10.96% year-over-year, with the annual reading at $13.4 billion for FY2025, 10.96% up from the prior year.
  • Accumulated Depreciation & Amortization hit $13.4 billion in Q4 2025 for Abbott Laboratories, up from $13.3 billion in the prior quarter.
  • In the past five years, Accumulated Depreciation & Amortization ranged from a high of $13.4 billion in Q4 2025 to a low of $9.9 billion in Q1 2021.
  • Historically, Accumulated Depreciation & Amortization has averaged $11.5 billion across 5 years, with a median of $11.5 billion in 2023.
  • Biggest five-year swings in Accumulated Depreciation & Amortization: rose 13.59% in 2021 and later increased 2.57% in 2022.
  • Year by year, Accumulated Depreciation & Amortization stood at $10.4 billion in 2021, then grew by 6.2% to $11.0 billion in 2022, then grew by 6.6% to $11.8 billion in 2023, then increased by 2.57% to $12.1 billion in 2024, then grew by 10.96% to $13.4 billion in 2025.
  • Business Quant data shows Accumulated Depreciation & Amortization for ABT at $13.4 billion in Q4 2025, $13.3 billion in Q3 2025, and $13.1 billion in Q2 2025.